Old Web
English
Sign In
Acemap
>
authorDetail
>
W. S. van der Hel
W. S. van der Hel
Novartis
Multiple sclerosis
Physical therapy
Medicine
Expanded Disability Status Scale
Resource consumption
2
Papers
43
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands
2013
Journal of Medical Economics
Korinna Karampampa
Anders Gustavsson
Erik van Munster
Raymond Hupperts
Evert Sanders
Jop Mostert
Okke L. G. F. Sinnige
Jaap de Graaf
Paul Pop
Carolin Miltenburger
Martijn Groot
Milon Relleke
W. S. van der Hel
Show All
Source
Cite
Save
Citations (33)
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
2012
Journal of Medical Economics
Marieke Heisen
Mj Treur
W. S. van der Hel
S.T.F.M. Frequin
Martijn Groot
Bg Verheggen
Show All
Source
Cite
Save
Citations (10)
1